Core Viewpoint - The article emphasizes the promising potential of microbiome-based therapies, particularly probiotics, in the prevention and treatment of colorectal cancer (CRC) by optimizing gut microbiota structure and enhancing immune response [2][12]. Group 1: Research Findings - A study published by Fudan University’s team demonstrated that the probiotic supplement CBM588 showed good tolerance in CRC patients undergoing radical surgery, promoting postoperative gut function recovery and reducing infection complications [4][10]. - CBM588, which contains Clostridium butyricum, was initially developed to alleviate common gastrointestinal diseases in East Asia and has shown significant synergistic effects in cancer immunotherapy [6][7]. - The recent clinical trial evaluated CBM588 as a perioperative adjunct therapy for CRC, focusing on postoperative gut function and immune status [8][9]. Group 2: Clinical Trial Results - The trial results indicated that perioperative use of CBM588 significantly improved gut function recovery and reduced the risk of infection complications, while also enhancing systemic immunity by increasing circulating T cells [9][12]. - The study concluded that CBM588 is a promising probiotic with good tolerance in CRC patients post-surgery, highlighting its potential clinical application and the need for further functional research [10][12].